1.

2.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
by Dimopoulos, Meletios A
The lancet oncology, 2017, Vol.18 (10), p.1327-1337

3.
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
by Temel, Jennifer S, Dr
The lancet oncology, 2016, Vol.17 (4), p.519-531

4.
Targeted Protein Degradation by Small Molecules
by Bondeson, Daniel P. Daniel P.
Annual review of pharmacology and toxicology, 2016, Vol.57, p.107-123

5.
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected...
by Molina, Jean-Michel, Prof
The Lancet (British edition), 2008, Vol.372 (9639), p.646-655

6.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoprox...
by DeJesus, Edwin
The Lancet (British edition), 2012, Vol.379 (9835), p.2429-2438

7.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed b...
by Gay, Francesca
The lancet oncology, 2021, Vol.22 (12), p.1705-1720

8.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
by Luabeya, Angelique Kany Kany
Vaccine, 2015, Vol.33 (33), p.4130-4140

9.
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
by Pearlman, Brian L, Dr
The Lancet infectious diseases, 2012, Vol.12 (9), p.717-728

10.
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
by Saadoun, David
Annals of the rheumatic diseases, 2014, Vol.73 (5), p.831-837

11.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomi...
by Usmani, Saad Z
The lancet oncology, 2022, Vol.23 (1), p.65-76

12.
Critical Roles of Kisspeptins in Female Puberty and Preovulatory Gonadotropin Surges as Revealed by a Novel Antagonist
by Pineda, R
Endocrinology (Philadelphia), 2010, Vol.151 (2), p.722-730

13.
Antiretroviral drug exposure in the female genital tract : implications for oral pre-and post-exposure prophylaxis
by DUMOND, Julie B
AIDS (London), 2007, Vol.21 (14), p.1899-1907

14.
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
by Cohen, Yael C
Nature medicine, 2021, Vol.27 (3), p.491-503

15.
An Increase in Kisspeptin-54 Release Occurs with the Pubertal Increase in Luteinizing Hormone-Releasing Hormone-1 Release in the Stalk-Median Eminence of Female Rhesus Monkeys in V...
by Keen, Kim L
Endocrinology (Philadelphia), 2008, Vol.149 (8), p.4151-4157

16.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
by Geldenhuys, Hennie
Vaccine, 2015, Vol.33 (30), p.3592-3599

17.
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events
by D'Arminio Monforte, Antonella
AIDS (London), 2013, Vol.27 (3), p.407-415

18.
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials
by Norrby, Maria
Vaccine, 2017, Vol.35 (12), p.1652-1661

19.
A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administra...
by Morimoto, Bruce H
Dementia and geriatric cognitive disorders, 2013, Vol.35 (5-6), p.325-339

20.
